LIFECORE BIOMEDICAL, INC. Business Combination, Consideration Transferred
LIFECORE BIOMEDICAL, INC. (LFCR) reported Business Combination, Consideration Transferred of $66.83 million for the 0-month period ending 2012-08-23, per its 10-Q filed 2014-03-28.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2014-03-28
- 2012-08-23: Business Combination, Consideration Transferred 0 month $66.83M.
| Period end | Business Combination, Consideration Transferred 0 month |
|---|---|
| 2012-08-23 | $66.83M 10-Q · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |